Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2023-02-24 Regulatory Filings
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2023-02-24 English
FORM 10-K
Annual Report FY 2022
2023-02-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a Regulation FD Disclosure about a press release announcing a webinar by AEON Biopharma, Inc. The document does not contain financial statements or detailed financial data but rather announces an event and includes a press release as an exhibit. The length is 4674 characters, which is relatively short and consistent with an announcement rather than a full report. The document explicitly states that the information is "furnished" and not "filed" for certain regulatory purposes, indicating it is an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-02-14 English
425 Filing
Regulatory Filings
2023-02-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a special meeting of stockholders, approval of an amendment to the certificate of incorporation extending the date for a business combination, voting results, and redemption of shares. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Earnings Release, M&A filings, or Board/Management changes. The document is primarily an announcement of corporate actions and voting results related to shareholder matters. Given the nature of the content and the form type, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2023-02-10 English
Merger & Acquisition 2023
Merger & Acquisition Classification · 95% confidence The document is a detailed response letter from a law firm to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a Registration Statement on Form S-4 filed by Priveterra Acquisition Corp. The letter addresses SEC staff comments on the amended registration statement, which is a proxy statement/prospectus related to a business combination (merger). The document includes detailed discussions on financial forecasts, risk factors, due diligence, valuation, and accounting treatment related to the merger transaction. The presence of the Form S-4 and the focus on merger-related disclosures and financial information indicate this is a filing related to a merger transaction. The document is not the merger proxy statement itself but a comment letter response, which is part of the regulatory review process for merger filings. However, given the detailed nature and length (15,000 characters) and the content focusing on merger disclosures and financial information, the best fitting category is Merger & Acquisition (MA), which covers merger, acquisition, and tender-offer filings such as Form S-4 and related communications. It is not a simple announcement or a proxy solicitation but a regulatory filing related to the merger process. Therefore, the classification is MA with high confidence.
2023-02-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.